TuHURA Biosciences (NASDAQ:HURA) Upgraded at Wall Street Zen
by Danessa Lincoln · The Markets DailyWall Street Zen upgraded shares of TuHURA Biosciences (NASDAQ:HURA – Free Report) from a sell rating to a hold rating in a research note issued to investors on Monday morning.
A number of other research analysts have also recently issued reports on HURA. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of TuHURA Biosciences in a report on Tuesday, February 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $9.00.
Get Our Latest Stock Analysis on HURA
TuHURA Biosciences Stock Down 9.5%
NASDAQ:HURA opened at $1.62 on Monday. The firm’s fifty day simple moving average is $1.36 and its 200-day simple moving average is $1.64. The stock has a market cap of $98.37 million, a PE ratio of -2.57 and a beta of -0.32. TuHURA Biosciences has a fifty-two week low of $0.41 and a fifty-two week high of $4.44.
TuHURA Biosciences (NASDAQ:HURA – Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01).
Institutional Investors Weigh In On TuHURA Biosciences
Several institutional investors and hedge funds have recently made changes to their positions in HURA. Vanguard Group Inc. grew its stake in TuHURA Biosciences by 1.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,269,666 shares of the company’s stock valued at $5,629,000 after acquiring an additional 35,426 shares during the last quarter. Geode Capital Management LLC raised its position in TuHURA Biosciences by 6.4% during the fourth quarter. Geode Capital Management LLC now owns 662,481 shares of the company’s stock worth $501,000 after acquiring an additional 39,710 shares during the last quarter. State Street Corp raised its position in TuHURA Biosciences by 4.9% during the fourth quarter. State Street Corp now owns 289,133 shares of the company’s stock worth $219,000 after acquiring an additional 13,594 shares during the last quarter. Apollon Wealth Management LLC lifted its holdings in shares of TuHURA Biosciences by 15.8% in the third quarter. Apollon Wealth Management LLC now owns 133,526 shares of the company’s stock valued at $331,000 after purchasing an additional 18,252 shares in the last quarter. Finally, Deutsche Bank AG lifted its holdings in shares of TuHURA Biosciences by 209.8% in the fourth quarter. Deutsche Bank AG now owns 79,816 shares of the company’s stock valued at $61,000 after purchasing an additional 54,051 shares in the last quarter. 0.62% of the stock is currently owned by hedge funds and other institutional investors.
TuHURA Biosciences Company Profile
TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.
At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.